Table 2.

Meta-analysis of the NFKB1 −94ins/del ATTG promoter polymorphism and cancer risk.

Variables	n a	Cases/Controls	ins/ins versus del/del		ins/del versus del/del		ins/ins + ins/del versus del/del (dominant)		ins/ins versus ins/del + del/del (recessive)		ins allele versus del allele
			OR (95% CI)	I 2 (%)	OR (95% CI)	I 2 (%)	OR (95% CI)	I 2 (%)	OR (95% CI)	I 2 (%)	OR (95% CI)	I 2 (%)
Total	21	6127/9239	1.47 (1.11–1.93) b	84.8	1.15 (0.97–1.37)b	67.7	1.26 (1.03–1.53) b	77.5	1.26 (1.05–1.51) b	82.3	1.19 (1.05–1.35) b	84.0
Cancer types
Bladder cancer	3	1058/1175	1.07 (0.45–2.53)b	90.1	1.00 (0.46–2.18)b	88.8	1.04 (0.46–2.33)b	90.7	1.04 (0.73–1.48)b	72.7	1.03 (0.70–1.51)b	89.0
Colorectal cancer	4	1275/1890	0.84 (0.47–1.50)b	82.9	0.93 (0.77–1.13)	0	0.88 (0.73–1.06)	0	0.89 (0.51–1.55)b	88.9	0.90 (0.72–1.12)b	76.2
Ovarian cancer	2	366/444	2.57 (1.66–3.98)	0	1.88 (1.23–2.89)	0	2.17 (1.45–3.25)	0	1.59 (1.19–2.11)	0	1.55 (1.27–1.90)	0
Oral cancer	2	674/721	2.10 (1.54–2.87)	33.0	1.42 (1.10–1.83)	0	1.59 (1.25–2.03)	3.9	1.67 (1.29–2.17)	0	1.43 (1.23–1.66)	6.9
Prostate cancer	2	451/477	1.59 (1.09–2.33)	23.0	1.28 (0.89–1.84)	28.6	1.40 (1.00–1.98)	35.8	1.33 (1.01–1.74)	0	1.26 (1.05–1.52)	0
Other cancers	8	2303/4532	1.72 (1.13–2.61) b	80.9	1.16 (0.88–1.53)b	61.3	1.34 (0.99–1.83) b	72.4	1.46 (1.12–1.90) b	78.0	1.29 (1.07–1.57) b	79.9
Ethnicities
Asian	14	4143/5169	1.83 (1.30–2.57) b	84.8	1.23 (0.97–1.58)b	75.9	1.42 (1.08–1.86) b	82.5	1.50 (1.26–1.78) b	66.8	1.32 (1.14–1.54) b	82.2
Caucasian	7	1984/4070	0.90 (0.64–1.27)b	71.2	1.00 (0.85–1.18)	18.5	0.95 (0.81–1.10)	24.0	0.90 (0.66–1.23)b	83.7	0.95 (0.82–1.12)b	70.9

^aNumber of comparisons.

^bRandom effects estimate.